Previous 10 | Next 10 |
Global Blood Therapeutics (NASDAQ:GBT) Oxbryta was approved by the European Commission (EC) to treat hemolytic anemia due to sickle cell disease (SCD) in patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide (hydroxyurea). The company said Oxbryta (vox...
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the European Commission (EC) has granted Marketing Authorization for Oxbryta ® (voxelotor) for the treatment of hemolytic anemia due to sickle...
Guerbet Announces Appointment of Jared Houk as Commercial Vice President for North America PR Newswire PRINCETON, N.J. , Jan. 12, 2022 /PRNewswire/ -- Guerbet LLC, the US affiliate of Guerbet, announced today that Jared Houk has been appointed Commercial Vice...
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced Oxbryta ® (voxelotor) tablets for oral suspension, a new dispersible, once-daily tablet dosage form recently approved by the U.S. Food and Dru...
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 40 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 11:15 a.m. E.T. The presentation and Q...
Amid the 2021 Biotech Bear market, GBT shares are still trading at a deep bargain to their true worth. Accumulating shares during a market downturn and patiently holding into the next market upcycle usually delivers outstanding returns. Like Santa Claus, the FDA delivered an early...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Global Blood Therapeutics (GBT +7.1%) is trading higher after the FDA expanded the approval for the company’s sickle cell disease therapy Oxbryta (voxelotor), allowing its use in children as young as four years of age. Oxbryta was cleared under the FDA’s accelerated pathway...
New dispersible tablet dosage form also approved Oxbryta is the first medicine that addresses the root cause of red blood cell sickling SOUTH SAN FRANCISCO, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced...
Global Blood Therapeutics (NASDAQ:GBT) announced that an expert panel of the European Medicines Agency (EMA) recommended the approval for the company’s oral drug Oxbryta (voxelotor) for hemolytic anemia due to sickle cell disease (SCD). EMA’s Medicinal Products for Human Use (CH...
News, Short Squeeze, Breakout and More Instantly...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
Global Blood Therapeutics Inc. Website:
Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...
The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...
NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...